Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cangrelor P2Y12 inhibitor · 1 trial · 3 indications
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat \[mITT\] population)
| Arm | Type | Description |
|---|---|---|
| cangrelor | EXPERIMENTAL | Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours. Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered. |
| clopidogrel | ACTIVE_COMPARATOR | Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion. During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm. |
| Name | Type | Description |
|---|---|---|
| cangrelor P2Y12 (platelet) inhibitor | DRUG | - |
| Clopidogrel - 300 or 600 mg (study arm) | DRUG | Over encapsulated tablets. |
| Clopidogrel 600 mg post cangrelor | DRUG | over-encapsulated clopidogrel (600 mg) |
Inclusion Criteria: Patients may be included in the study if they meet all of the following criteria: * Male or non-pregnant female at least 18 years of age * Patients undergoing percutaneous coronary intervention (PCI): 1. Stable angina (SA) patients with diagnostic coronary angiography within...
Cangrelor is an investigational small molecule being studied for use in atherosclerosis, specifically in patients who require percutaneous coronary intervention (PCI) and those with acute coronary syndrome. It is a P2Y12 inhibitor that has completed a Phase 3 clinical trial.
Cangrelor targets the P2Y12 receptor, a key player in platelet activation and aggregation. By inhibiting this receptor, cangrelor aims to prevent blood clots in patients undergoing percutaneous coronary intervention for atherosclerosis.
Cangrelor is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. The drug is currently in Phase 3 clinical development for cardiovascular indications.
Cangrelor is in Phase 3 clinical development. It has completed one Phase 3 trial, the CHAMPION PHOENIX study, which enrolled 11,145 patients. The drug is investigational and has not yet been approved by regulatory authorities.
Cangrelor has been studied in one completed Phase 3 clinical trial, NCT01156571, known as CHAMPION PHOENIX. This randomized, double-blind, active-controlled trial compared cangrelor to clopidogrel standard therapy in subjects requiring percutaneous coronary intervention.
No, cangrelor is not the same as clopidogrel. Both are P2Y12 inhibitors used in cardiovascular procedures, but they are distinct drugs. In the CHAMPION PHOENIX trial, cangrelor was compared directly against clopidogrel as the active control.